| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
H-Gly-NH2.HCl is classified as a glycine amide analogue. It does not have a specific biological receptor target. Its primary application is as a building block in peptide synthesis and bioconjugation research. The amide group at the C-terminus provides a different functionality compared to the free acid, enabling the synthesis of peptide amides and other derivatives. It is also used as a pharmaceutical intermediate.
|
|---|---|
| ln Vitro |
In vitro activity for H-Gly-NH2.HCl is primarily as a peptide synthesis reagent and buffer. Amino acids and amino acid derivatives have been commercially used as ergogenic supplements. They influence the secretion of anabolic hormones, supply of fuel during exercise, mental performance during stress-related tasks and prevent exercise-induced muscle damage. H-Gly-NH2.HCl itself is not directly biologically active; its utility is in preparing glycine amide-containing compounds for subsequent biological evaluation.
|
| ln Vivo |
In vivo activity data for H-Gly-NH2.HCl as a standalone compound is not applicable. It is a glycine amide derivative used exclusively as a research building block and is not intended for direct in vivo administration. It is a key raw material for the preparation of the novel central nervous system drug oxiracetam, which has clinical applications in treating vascular dementia, senile dementia, and brain trauma-related memory and intelligence disorders.
|
| Enzyme Assay |
In vitro synthetic protocols for H-Gly-NH2.HCl involve its use as a building block in peptide synthesis. The compound can be coupled to other amino acids or molecules using standard peptide coupling chemistry. The amide group provides a different reactivity profile compared to the free acid. Purity is typically ≥95%. Density is 1.122 g/cm3.
|
| Cell Assay |
Cell-based protocols are not directly applicable to H-Gly-NH2.HCl as it is a synthetic building block. Compounds synthesized using this reagent can be tested in cell culture. Compounds are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
Animal studies with H-Gly-NH2.HCl are not conducted directly. The compound may be used as a synthetic intermediate to prepare compounds such as oxiracetam for in vivo evaluation. Standard synthetic chemistry protocols are used to convert this intermediate into target molecules for pharmaceutical research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for H-Gly-NH2.HCl as a standalone compound is not applicable. The compound has a molecular weight of 110.54 g/mol, formula C2H7ClN2O, and CAS number 1668-10-6. Melting point is 204-212°C. Storage is recommended long-term in a cool, dry place.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for H-Gly-NH2.HCl. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions for handling laboratory chemicals should be observed. No specific toxicity studies have been reported.
|
| Additional Infomation |
H-Gly-NH2.HCl (CAS#: 1668-10-6) is also known as Glycinamide hydrochloride, 2-Aminoacetamide hydrochloride, and Glycine amide hydrochloride. Its molecular formula is C2H7ClN2O. It is a key raw material for the synthesis of oxiracetam. It has no approved therapeutic indications.
|
| Molecular Formula |
C2H7CLN2O
|
|---|---|
| Molecular Weight |
110.5428
|
| Exact Mass |
110.024
|
| CAS # |
1668-10-6
|
| PubChem CID |
2723639
|
| Appearance |
White to off-white powder
|
| Density |
1.122g/cm3
|
| Boiling Point |
281.3ºC at 760mmHg
|
| Melting Point |
204 °C (dec.)(lit.)
|
| Vapour Pressure |
0.00359mmHg at 25°C
|
| LogP |
0.633
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
6
|
| Complexity |
42.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O=C(C([H])([H])N([H])[H])N([H])[H]
|
| InChi Key |
WKNMKGVLOWGGOU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2H6N2O.ClH/c3-1-2(4)5;/h1,3H2,(H2,4,5);1H
|
| Chemical Name |
2-aminoacetamide;hydrochloride
|
| Synonyms |
Glycinamide hydrochloride; 2-Aminoacetamide hydrochloride; H-Gly-NH2.HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~904.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.0465 mL | 45.2325 mL | 90.4650 mL | |
| 5 mM | 1.8093 mL | 9.0465 mL | 18.0930 mL | |
| 10 mM | 0.9046 mL | 4.5232 mL | 9.0465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
